Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
- Resource Type
- Article
- Authors
- Cloughesy, Timothy F.; Landolfi, Joseph; Hogan, Daniel J.; Bloomfield, Stephen; Carter, Bob; Chen, Clark C.; Elder, J. Bradley; Kalkanis, Steven N.; Kesari, Santosh; Lai, Albert; Lee, Ian Y.; Liau, Linda M.; Mikkelsen, Tom; Nghiemphu, Phioanh Leia; Piccioni, David; Walbert, Tobias; Chu, Alice; Das, Asha; Diago, Oscar R.; Gammon, Dawn
- Source
- Science Translational Medicine; 6/1/2016, Vol. 8 Issue 341, p1-11, 11p, 1 Color Photograph, 4 Charts, 3 Graphs
- Subject
- GLIOMA treatment
CANCER cells
RNA analysis
CYTOSINE deaminase
CANCER treatment
- Language
- ISSN
- 19466234
The article presents the results of the phase 1 study of Toca 511 (vocimagene amiretrorepvec) and 5-fluorocytosine (FC) for recurrent high-grade glioma. It states that treatment of Toca 511 resulted in viral transduction of tumor cells as demonstrated by detection of Toca 511 DNA and expression of Toca 511 RNA and cytosine deaminase (CD) protein. It mentions that the median duration of treatment with Toca FC was two cycles.